Support The Moscow Times!

Russia’s Sputnik V Vaccine Is 91.4% Effective, Developers Confirm

The developers claim that Sputnik V vaccine is 91.4% effective. Sergei Kiselyov / Moskva News Agency

Russia’s Sputnik V coronavirus vaccine is 91.4% effective, its developers announced Monday, citing a new analysis of data from its Phase 3 clinical trials.

The state-run Gamaleya National Center of Epidemiology and Microbiology in Moscow that developed Sputnik V said the data was obtained 21 days after volunteers received the first dose of the two-shot vaccine. The latest 91.4% figure is lower than its previously reported effectiveness of 96.2%.

“The vaccine demonstrated 100% efficacy against severe coronavirus cases. There were 20 severe cases of coronavirus infection among confirmed cases in the placebo group and no severe cases in the vaccine group,” Gamaleya said in a press release. 

Data obtained at the third and final control point will be published in the near future in a “leading international peer-reviewed medical journal,” Gamaleya said. 

The statement added that developers will use this data to seek accelerated registration for the vaccine in other countries.

The Russian-developed Sputnik V has drawn skepticism at home and abroad after it was rushed through government approval before the start of its large-scale Phase 3 trials. In September, scientists from several countries signed a note of concern over possible data manipulation and statistical anomalies in its Phase 1/2 data published in medical journal The Lancet. Its developers defended their research, saying that the methods they used to obtain measurements give only rough values, not exact numbers.

Phase 3 trials of the adenovirus vector-based vaccine will involve 40,000 volunteers in Moscow. About 26,000 volunteers have already been vaccinated in Russia for the Phase 3 trials with “no unforeseen adverse effects documented,” the Russian Direct Investment Fund that is funding Sputnik V’s development reported. 

Russia launched its large-scale vaccination campaign starting with at-risk groups last week as ordered by President Vladimir Putin. The announcement came shortly after Britain issued the world’s first general-use approval to the Pfizer-BioNTech vaccine. 

… we have a small favor to ask. As you may have heard, The Moscow Times, an independent news source for over 30 years, has been unjustly branded as a "foreign agent" by the Russian government. This blatant attempt to silence our voice is a direct assault on the integrity of journalism and the values we hold dear.

We, the journalists of The Moscow Times, refuse to be silenced. Our commitment to providing accurate and unbiased reporting on Russia remains unshaken. But we need your help to continue our critical mission.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and you can be confident that you're making a significant impact every month by supporting open, independent journalism. Thank you.

paiment methods
Not ready to support today?
Remind me later.

Read more